Dyne Therapeutics Inc.

NASDAQ: DYN · Real-Time Price · USD
12.19
-0.14 (-1.14%)
At close: Aug 19, 2025, 11:50 AM

Dyne Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
n/a n/a n/a n/a n/a n/a 3.79M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost of Revenue
n/a n/a n/a n/a 400K 386K 567K 597K 674K 623K 615K 397K 1.64M 1.47M 341K 260K 241K 231K
Gross Profit
n/a n/a n/a n/a -400K -386K 3.22M -597K -674K -623K -615K -397K -1.64M -1.47M -341K -260K -241K -231K
Operating Income
-115.79M -122.37M -97.11M -105.66M -71.96M -69.16M -67.69M -62.27M -66.74M -45.46M -40.15M -42.28M -52.76M -35.78M -51.96M -42.77M -30.16M -25.13M
Interest Income
6.63M 7.1M 7.59M 9.28M 7.05M 3M 1.75M 2.19M 2.21M 1.49M 1.34M 903K 441K 230K 182K 184K 210K 166K
Pretax Income
-110.86M -115.36M -89.54M -97.13M -65.1M -65.65M -66.64M -60.21M -64.9M -44.19M -38.83M -41.38M -52.3M -35.58M -51.79M -42.58M -29.95M -24.97M
Net Income
-110.86M -115.36M -89.54M -97.13M -65.1M -65.65M -66.64M -60.21M -64.9M -42.5M -37.51M -40.49M -52.3M -35.38M -51.79M -42.58M -29.95M -24.97M
Selling & General & Admin
16.55M 15.93M 15.3M 12.86M 9.7M 24.62M 8.28M 7.02M 7.61M 7.93M 6.96M 7.61M 6.09M 7.55M 9.66M 6.26M 6.29M 6.51M
Research & Development
99.24M 106.45M 81.81M 92.8M 62.26M 44.54M 58.84M 55.25M 59.13M 37.54M 33.19M 34.67M 46.66M 28.24M 42.3M 36.51M 23.87M 18.63M
Other Expenses
n/a n/a n/a n/a n/a 506K n/a n/a -373K 1.28M 1.32M -9K 10K n/a 175K n/a n/a n/a
Operating Expenses
115.79M 122.37M 97.11M 105.66M 71.96M 69.16M 67.12M 62.27M 66.74M 45.46M 40.15M 42.28M 52.76M 35.78M 51.96M 42.77M 30.16M 25.13M
Interest Expense
-94K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a n/a n/a -567K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
n/a 122.37M 97.89M 105.66M 71.96M 69.16M 67.69M 62.27M 66.74M 45.46M 40.15M 42.28M 52.76M 35.78M 51.96M 42.77M 30.16M 25.13M
Income Tax Expense
n/a n/a n/a n/a n/a n/a n/a -431K n/a -1.69M -1.32M -894K -441K -200K 182K 184K 210K 166K
Shares Outstanding (Basic)
113.87M 109.91M 101.98M 100.88M 92.51M 81.04M 61.39M 61.11M 59.84M 56.33M 52.47M 51.8M 51.68M 51.6M 51.54M 51.32M 51.22M 49.47M
Shares Outstanding (Diluted)
113.87M 109.91M 101.98M 100.88M 92.51M 81.04M 61.39M 61.11M 59.84M 56.33M 52.47M 51.8M 51.68M 51.6M 51.54M 51.32M 51.22M 49.47M
EPS (Basic)
-0.97 -1.05 -0.88 -0.96 -0.7 -0.81 -1.09 -0.99 -1.08 -0.75 -0.71 -0.78 -1.01 -0.69 -1 -0.83 -0.58 -0.5
EPS (Diluted)
-0.97 -1.05 -0.88 -0.96 -0.7 -0.81 -1.09 -0.99 -1.08 -0.75 -0.71 -0.78 -1.01 -0.69 -1 -0.83 -0.58 -0.5
EBITDA
-115.79M -121.87M -96.66M -105.22M -71.96M -68.77M -67.29M -61.84M -66.31M -45.05M -40.15M -41.88M -52.3M -35.36M -51.45M -42.51M -29.92M -24.9M
EBIT
n/a -122.37M -97.11M -105.66M -71.96M -69.16M -67.69M -62.27M -66.74M -45.46M -40.14M -42.28M -52.76M -35.78M -51.79M -42.77M -29.95M -24.97M
Depreciation & Amortization
n/a 502K 450K 438K 399K 386K 567K 597K 674K 623K 615K 397K 1.64M 1.47M 341K 260K 241K 231K